The FDA issued a complete response letter (CRL) to Corcept Therapeutics for relacorilant in patients with hypertension secondary to hypercortisolism (Cushing syndrome), requesting additional evidence of efficacy. Corcept disclosed the CRL publicly and said it will meet with the agency to define a path forward. Investors reacted sharply, reflecting the regulatory setback. Corcept now refocused resources toward a separate regulatory program: seeking approval of relacorilant in platinum-resistant ovarian cancer with a July 2026 PDUFA target. The company’s shift underscores a common industry playbook when primary indications face regulatory hurdles — pursuing oncology or other higher-unmet-need indications where benefit-risk may be more favorable.